A Phase 3 trial evaluating the triple combination of U2 plus venetoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors TG Therapeutics Inc
- 05 Mar 2021 New trial record
- 02 Mar 2021 According to a TG Therapeutics Inc media release, this study is expected to begin in 2021.